caa a22 4500 44531379X CHVBK 20180317142639.0 cr unu---uuuuu 170323e20110501xx s 000 0 eng 10.1007/s11095-011-0372-2 doi (NATIONALLICENCE)springer-10.1007/s11095-011-0372-2 Diclofenac Enables Prolonged Delivery of Naltrexone Through Microneedle-Treated Skin [Elektronische Daten] [Stan Banks, Kalpana Paudel, Nicole Brogden, Charles Loftin, Audra Stinchcomb] ABSTRACT: Purpose: The purpose of this study was to determine if non-specific COX inhibition could extend pore lifetime in hairless guinea pigs following microneedle treatment. Methods: Hairless guinea pigs were treated with microneedle arrays ± daily application of Solaraze® gel (3% diclofenac sodium (non-specific COX inhibitor) and 2.5% hyaluronic acid); transepidermal water loss was utilized to evaluate pore lifetime. To examine the permeation of naltrexone, additional guinea pigs were treated with microneedles ± daily Solaraze® gel followed by application of a 16% transdermal naltrexone patch; pharmacokinetic analysis of plasma naltrexone levels was performed. Histological analysis was employed to visualize morphological changes following microneedle and Solaraze® treatment. Results: Animals treated with microneedles + Solaraze® displayed extended pore lifetime (determined by transepidermal water loss measurements) for up to 7days. Enhanced naltrexone permeation was also observed for an extended amount of time in animals treated with microneedles + Solaraze®. No morphological changes resulting from microneedle treatment or COX inhibition were noted. Conclusions: Non-specific COX inhibition is an effective means of extending pore lifetime following microneedle treatment in hairless guinea pigs. This may have clinical implications for extending transdermal patch wear time and therefore increasing patient compliance with therapy. Springer Science+Business Media, LLC, 2011 cyclooxygenase nationallicence microneedle nationallicence micropore nationallicence naltrexone nationallicence Banks Stan AllTranz, Inc., Lexington, Kentucky, USA aut Paudel Kalpana Department of Pharmaceutical Sciences, College of Pharmacy, University of Kentucky, 459 Wethington Bldg., 900 South Limestone Street, 40536, Lexington, Kentucky, USA aut Brogden Nicole Department of Pharmaceutical Sciences, College of Pharmacy, University of Kentucky, 459 Wethington Bldg., 900 South Limestone Street, 40536, Lexington, Kentucky, USA aut Loftin Charles Department of Pharmaceutical Sciences, College of Pharmacy, University of Kentucky, 459 Wethington Bldg., 900 South Limestone Street, 40536, Lexington, Kentucky, USA aut Stinchcomb Audra AllTranz, Inc., Lexington, Kentucky, USA aut Pharmaceutical Research Springer US; http://www.springer-ny.com 28/5(2011-05-01), 1211-1219 0724-8741 28:5<1211 2011 28 11095 https://doi.org/10.1007/s11095-011-0372-2 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/s11095-011-0372-2 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Banks Stan AllTranz, Inc., Lexington, Kentucky, USA aut NATIONALLICENCE 700 1- Paudel Kalpana Department of Pharmaceutical Sciences, College of Pharmacy, University of Kentucky, 459 Wethington Bldg., 900 South Limestone Street, 40536, Lexington, Kentucky, USA aut NATIONALLICENCE 700 1- Brogden Nicole Department of Pharmaceutical Sciences, College of Pharmacy, University of Kentucky, 459 Wethington Bldg., 900 South Limestone Street, 40536, Lexington, Kentucky, USA aut NATIONALLICENCE 700 1- Loftin Charles Department of Pharmaceutical Sciences, College of Pharmacy, University of Kentucky, 459 Wethington Bldg., 900 South Limestone Street, 40536, Lexington, Kentucky, USA aut NATIONALLICENCE 700 1- Stinchcomb Audra AllTranz, Inc., Lexington, Kentucky, USA aut NATIONALLICENCE 773 0- Pharmaceutical Research Springer US; http://www.springer-ny.com 28/5(2011-05-01), 1211-1219 0724-8741 28:5<1211 2011 28 11095 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer